We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01756898
First Posted: December 28, 2012
Last Update Posted: November 6, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.
  Purpose
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.

Condition Intervention Phase
Atopic Dermatitis Drug: ASB17061 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by Daiichi Sankyo, Inc.:

Primary Outcome Measures:
  • Investigator's Global Assessment (IGA) [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Eczema Area and Severity Index Score (EASI) [ Time Frame: 8 weeks ]
  • The Percentage of Body Surface Area (BSA) Involved [ Time Frame: 8 weeks ]
  • Pruritus Score [ Time Frame: 8 weeks ]
  • Insomnia Score [ Time Frame: 8 weeks ]
  • Number of Patients with Abnormal Findings in Electrocardiograms, Serum Biomarkers, Clinical Laboratory Test, and Vital Signs [ Time Frame: 8 weeks ]
  • Population Pharmacokinetics: AUC and Cavg [ Time Frame: 4 weeks ]
  • Number of Patients with Adverse Events [ Time Frame: 8 weeks ]

Enrollment: 370
Study Start Date: December 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose ASB17061
Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: Middle dose ASB17061
Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: High dose ASB17061
Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Placebo Comparator: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.
Drug: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult subjects ages 18 to 65 years
  • A diagnosis of atopic dermatitis (AD)
  • An IGA score of 2 or higher and AD affecting at least 5% of total Body Surface Area (BSA)
  • Other than active AD, in good health with no medical condition that may jeopardize the safety of the subject or impact the validity of the study results
  • Subjects must be practicing acceptable birth control methods

Exclusion Criteria:

  • Taking systemic immunosuppressive therapy within 3 months prior to screening or systemic (cortico) steroid therapy within 4 weeks prior to screening
  • Use of phototherapy or tanning beds within 6 weeks of screening
  • Presence of a clinically significant disorder involving gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition, which will jeopardize the safety of the subject or impact the validity of the study results
  • Female subjects who are pregnant or breastfeeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01756898


  Show 40 Study Locations
Sponsors and Collaborators
Daiichi Sankyo, Inc.
Investigators
Study Director: Ger Rikken, MD Asubio Pharmaceuticals, Inc.
  More Information

Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT01756898     History of Changes
Other Study ID Numbers: ASBI 704
First Submitted: November 9, 2012
First Posted: December 28, 2012
Last Update Posted: November 6, 2015
Last Verified: October 2015

Keywords provided by Daiichi Sankyo, Inc.:
Atopic Dermatitis
eczema

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases